论文部分内容阅读
目的:探讨131I治疗Craves病(GD)的最佳剂量方法并分析其中影响疗效的因素。方法:155例GD患者按最佳公式计算131I剂量。治疗前后进行示踪和治疗剂量的甲状腺摄碘率(TUR)和有效半衰期(EHL)测量,甲状腺重量采用显像(RI)及B超(US)重复测量。结果:131I治疗前后24hTUR和EHL综合影响为1.08。甲状腺重量下降率与治疗前重量关系呈弱正相关。临床治愈率为71.0%、未愈为29.0%。TGAb、TMAb阳性与阴性组比较正常、甲减和未愈均有差异。结论:GD131I疗效受不同给药方法的影响,甲状腺重量是最重要的一个参数。治疗前后TUR和EHL综合影响为1.08。甲状腺抗体在甲减的发生、发展过程中起一定的作用。迅速控制甲亢,而又要降低甲减率,难以兼顾。
Objective: To investigate the optimal dosage of 131I for treatment of Craves disease (GD) and to analyze the factors influencing curative effect. Methods: 155 cases of GD patients according to the best formula to calculate 131I dose. Thyroid uptake (TUR) and effective half-life (EHL) measurements of tracer and therapeutic doses were taken before and after treatment, and thyroid weights were measured with RI and US. Results: The combined effect of TUR and EHL was 1.08 before and after 131I treatment. Thyroid weight loss rate and weight before treatment showed a weak positive correlation. Clinical cure rate was 71.0%, unhealed 29.0%. TGAb, TMAb positive and negative group was normal, hypothyroidism and unhealed were different. Conclusion: The efficacy of GD131I is influenced by different administration methods. Thyroid weight is the most important parameter. The combined effect of TUR and EHL before and after treatment was 1.08. Thyroid antibodies in the occurrence of hypothyroidism, the development process plays a role. Rapid control of hyperthyroidism, but also reduce the hypothyroidism rate, it is difficult to take into account.